Here is an interesting approach that Gilead employed in a recent partnership with Galapagos -

"Another recent move was the drug discovery alliance it signed with Galapagos, exchanging $3.95bn up front and a $1.1bn equity stake in exchange for developmental and commercial rights to the Belgian biotech’s pipeline. As part of the deal, Gilead signed a declaration preventing it from increasing its holding of Galapagos shares beyond 30% within the next 10 years, ensuring its longterm independence. This unusual, de-risked arrangement provides Gilead with an attractive supplement to its own pipeline, while allowing Galapagos to remain focused, although the deal in itself is insufficient to plug a looming shortfall in product revenues."

There are a myriad of ideas to structure a deal palatable to all parties, ie., FDA, RVX, Zenith, Hepa, Eastern, PPs', Retail, RPShareholders, et.al., that can be employed to get apabetalone approved for a NDA. Once they have a revenue stream, the sky opens up.

Recent developments are very encouraging

Buyout or CoDevelopment Partnership? RVX only or RVX/Zenith? apabetalone only, ZEN-3694 only?

Chicagoest